-
公开(公告)号：KR1020110007540A
公开(公告)日：2011-01-24
申请号：KR1020090065107
申请日：2009-07-16
Applicant: (주)아모레퍼시픽
IPC: A61K8/49 , A61Q19/08 , A61K31/352 , A61P17/18
CPC classification number: A61K8/498 , A61K8/418 , A61K8/466 , A61K2800/522 , A61Q19/08
Abstract: PURPOSE: A composition for skin anti-aging is provided to suppress matrix metalloprotease activation without skin irritation. CONSTITUTION: A composition for skin anti-aging contains 0.01-20 weight% of compound of chemical formula 1, isomer or pharmaceutically acceptable salt thereof as an active ingredient. The composition is used for preventing or treating wrinkling and skin aging. The composition is a pharmaceutical composition or cosmetic composition. The pharmaceutical composition is manufactured in the form of lotion, ointment, gel, cream, patch or spray. The cosmetic composition is used in the form of essence, nutrition cream, massage cream, pack, gel, essence, eye cream, cleansing cream, cleansing foam, pack, and powder.
Abstract translation: 目的：提供皮肤抗衰老的组合物，以抑制基质金属蛋白酶活化而无皮肤刺激。 构成：用于皮肤抗衰老的组合物含有0.01-20重量％的化学式1的化合物，其异构体或其药学上可接受的盐作为活性成分。 该组合物用于预防或治疗皱纹和皮肤老化。 该组合物是药物组合物或化妆品组合物。 药物组合物以洗剂，软膏，凝胶，霜剂，贴剂或喷雾剂的形式制备。 化妆品组合物以精华，营养霜，按摩霜，包装，凝胶，精华，眼霜，清洁霜，清洁泡沫，包装和粉末的形式使用。
-
公开(公告)号：KR1020090056584A
公开(公告)日：2009-06-03
申请号：KR1020070123798
申请日：2007-11-30
Applicant: (주)아모레퍼시픽 , 재단법인서울대학교산학협력재단
CPC classification number: A61K31/16
Abstract: A pharmaceutical composition regulating the activity of sphingosylphosphorylcholine(SPC) is provided to regulate cell proliferation, inflammation and pruritus and treat inflammmatin or pruritus of dermatitis such as atopic dermatitis. A pharmaceutical composition which regulates the activity of sphingosylphosphorylcholine(SPC) comprises a compound of the chemical formula 1 or its pharmaceutically allowable salt. In the chemical formula 1, X is O or S, Y is CH2 or carbonyl. R1 is hydrogen or C1-10 alkyl, R2 is hydrogen or methyl, but when X is O, either R1 or R2 cannot be hydrogen, R3 is C1-4 alkyl. A method for manufacturing a compound of the chemical formula 1a comprises: a step of reacting a compound of the chemical formula 2 and a compound of the chemical formula 3 under the presence of base to obtain a compound of the chemical formula 4; a step of stirring the compound of the chemical formula 4 under the presence of base to obtain a compound of the chemical formula 5; and a step of performing the peptide bond between the compound of the chemical formula 5 and a compound of the chemical formula 6 to obtain the compound of the chemical formula 1a.
Abstract translation: 提供调节肌动蛋白磷酰胆碱（SPC）活性的药物组合物，用于调节细胞增殖，炎症和瘙痒，并治疗诸如特应性皮炎等炎性炎症或皮炎瘙痒症。 调节鞘糖基磷酰胆碱（SPC）活性的药物组合物包含化学式1的化合物或其药学上可允许的盐。 在化学式1中，X为O或S，Y为CH 2或羰基。 R1是氢或C1-10烷基，R2是氢或甲基，但当X是O时，R1或R2不能是氢，R3是C1-4烷基。 制备化学式1a化合物的方法包括：使化学式2的化合物与化学式3化合物在碱存在下反应得到化学式4的化合物的步骤; 在碱的存在下搅拌化学式4的化合物以获得化学式5的化合物的步骤; 在化学式5的化合物与化学式6的化合物之间进行肽键的步骤，得到化学式1a的化合物。
-
公开(公告)号：KR101736979B1
公开(公告)日：2017-05-19
申请号：KR1020100088082
申请日：2010-09-08
Applicant: (주)아모레퍼시픽
IPC: A61K36/73 , A61K36/736 , A61K8/97 , A61Q19/00
CPC classification number: A61K36/736 , A61K8/97 , A61K36/73 , A61Q19/00
Abstract: 본발명은오매(Prunus mume) 추출물을유효성분으로함유하는레이저시술후의애프터케어용피부외용제조성물을제공한다.본발명의피부외용제조성물은피부진정, 피부장벽회복및 통증완화효능을가지고있어서, 민감성피부보호, 피부민감성방지, 피부안정감제공및 보습효과를추가적으로가지는화장료조성물로개발될수 있다.
Abstract translation: 本发明提供一种含有梅的提取物作为有效成分的激光治疗后的护理用皮肤外用组合物本发明的皮肤外用组合物具有皮肤镇静，恢复皮肤屏障和缓解疼痛， 皮肤保护，皮肤敏感度，皮肤感觉和保湿效果。
-
公开(公告)号：KR1020170042905A
公开(公告)日：2017-04-20
申请号：KR1020150142099
申请日：2015-10-12
Applicant: (주)아모레퍼시픽
IPC: A61L27/14 , C08L101/16
CPC classification number: A61L27/14 , C08L101/16
Abstract: 본발명은기공형성유도물질과소수성생분해성고분자를휘발성용매에용해시키는것을포함하는고분자용액의제조단계; 상기고분자용액을물 또는상안정화제를포함하는수용액에분산시켜 O/W(Oil in Water) 형태의에멀젼(emulsion)을형성하는단계; 상기고분자용액이분산된수용액상에서휘발성용매를휘발시켜상기소수성생분해성고분자를고형화하여, 소수성생분해성고분자와상기기공형성유도물질간의자발적상분리를발생시켜 O/W(Oil in Water) 형태의에멀젼(emulsion)에포함된오일상고분자용액을 O/S(Oil in Solid) 미립구로변환시키는것을포함하는중공형다공성미립구의제조단계; 및상기중공형다공성미립구에포함된기공형성유도물질을제거하는단계를포함하는중공형다공성미립구의제조방법을제공한다.
Abstract translation: 本发明是一种用于制备聚合物溶液，其包含溶解步骤中的孔隙形成物质和诱导在挥发性溶剂中的疏水性可生物降解的聚合物; 形成聚合物溶液的乳液（乳液）分散在包含水或清洗剂sangan O / W（水油）形式的水溶液; 和由挥发性溶剂以固化在水溶液中，其中所述聚合物溶液分散在疏水性生物可降解聚合物的蒸发，疏水性可生物降解的生成乳液形式的聚合物和成孔诱导剂的O / W（水油）之间的自发相分离（ 乳液）制造其中包括将每天聚合物溶液共形多孔微球的O-阶段到O / S（包含在固体）微球体油; 它提供了一种生产去除包含在该共形多孔微球的诱导成孔材料的步骤的多孔微球的共形方法。
-
公开(公告)号：KR1020170038364A
公开(公告)日：2017-04-07
申请号：KR1020150137650
申请日：2015-09-30
Applicant: (주)아모레퍼시픽
Abstract: 본발명은중공관형태의관통구를포함하는침관, 상기침관이고정되는구멍을포함하는침기및 상기침관을관통하여침관의선단부에서봉합사를끼우기위한고리를형성하고실 양쪽끝단이침관의후단부로빠져나온유도실을포함하는피부시술도구및 키트에관한것이다. 본발명은봉합사를유도실이형성하는고리에끼움으로써, 침관의두께에영향받지않고다양한굵기또는형태를갖는봉합사의사용이가능하며, 종래두꺼운굵기의침관으로인해발생했던부작용을감소시키고피부시술효과를증대시킬수 있다. 또한, 유도실양쪽끝단을침관후단부로빠져나오게하여유도실고정부또는유도실고정덮개로고정함으로써피부시술시실밀림을방지할수 있다.
Abstract translation: 本发明chimgwan，包括一个通孔在该处形成通过chimgwan以形成用于在chimgwan渗透的远端部和所述容纳孔chimgwan嵌合缝线被固定的环和室中的chimgwan的后端的两端部 皮肤处理工具和包括引出室的套件。 本发明允许使用具有通过将缝线环到感应室具有不同的厚度或类型的缝合线形成，而不受所述chimgwan的厚度，并减少这在常规的厚的厚度和皮肤的治疗chimgwan发生因副作用 效果可以增加。 此外，通过固定两端感应室chimgwan后端部分衍生斯莱戈政府或固定到盖引导室被压出，以防止皮肤处理西西里丛林。
-
Patent Agency Ranking46.发明授权바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염, 및 이를 포함하는 약학 조성물 有权其新型化合物异构体或其药学上可接受的盐作为VANILLOID受体拮抗剂和含有该抗体的药物组合物
公开(公告)号：KR101621444B1
公开(公告)日：2016-05-19
申请号：KR1020117002414
申请日：2009-07-02
Applicant: (주)아모레퍼시픽
Inventor： 우병영 , 김선영 , 김연준 , 신송석 , 김진관 , 이기화 , 김동현 , 임경민 , 모주현 , 정연수 , 최진규 , 고현주 , 이정오 , 김혁 , 윤정훈 , 리,푸난 , 김지숙 , 서영거
IPC: C07D263/36 , C07D277/22 , A61K31/421 , A61P25/00
CPC classification number: C07D263/42 , C07D263/34 , C07D263/38 , C07D263/48 , C07D277/42 , C07D277/56 , C07D307/52 , C07D307/68 , C07D333/38 , C07D413/04 , C07D413/12
Abstract: 본발명은바닐로이드수용체(Vanilloid Receptor 1; VR1; TRPV1) 길항제로작용하는신규화합물, 이의이성질체또는이의약제학적으로허용가능한염; 및이를포함하는약학조성물에관한것이다. 본발명은통증, 편두통(migraine), 관절통(arthralgia), 신경통(neuralgia), 신경장해(neuropathies), 신경손상(nerve injury), 피부질환(skin disorder), 비뇨방광과민증(urinary bladder hypersensitiveness), 과민성대장증후군(irritable bowel syndrome), 절박배변(fecal urgency), 호흡기질환(respiratory disorder), 피부, 눈또는점막자극(irritation of skin, eye or mucous membrane), 위-십이지장궤양(stomach-duodenal ulcer), 염증질병(inflammatory diseases), 귓병(ear disease), 심장병(heartdisease) 등과같은질병의예방또는치료용약학조성물을제공한다.
-
公开(公告)号：KR101519649B1
公开(公告)日：2015-05-13
申请号：KR1020080059872
申请日：2008-06-24
Applicant: (주)아모레퍼시픽 , 서울대학교산학협력단
Abstract: 본 발명은 신경 통증감각 수용체(TRPV-1, VR1, Transient Receptor Potential family V-1)의 활성을 억제하는 단계를 포함하는 피부 미용방법, 피부 미용 물질 스크리닝(screening) 방법, 및 신경 통증감각 수용체의 활성을 억제하는 물질을 유효 성분으로 함유하는 피부 미용 조성물을 제공한다.
본 발명에 따르면, 신경 통증감각 수용체의 활성 억제를 통해 피부 미용을 증대시킬 수 있고, 피부 미용에 유효한 타겟 물질을 선정할 수 있으며, 선정된 물질은 신경 통증감각 수용체의 활성 억제로 인한 콜라겐 분해효소의 발현 감소, 피부 자극 완화, 및 혈행촉진을 유도할 수 있는 바, 피부 노화 방지 등을 통한 피부 미용에 특히 유효하다.
신경 통증감각 수용체, 피부 미용-
公开(公告)号：KR1020150001070A
公开(公告)日：2015-01-06
申请号：KR1020130073708
申请日：2013-06-26
Applicant: (주)아모레퍼시픽
IPC: A61K31/715 , A61K31/70 , A61K8/73 , A61P17/00
CPC classification number: A61K31/737 , A23L29/30 , A23V2200/318 , A61K8/73 , A61K9/0019 , A61K31/728
Abstract: 본 명세서는 글루코스아미노글라이칸의 하나인 콘드로이친설페이트와 히알루론산을 함유하는 콜라겐의 생성을 촉진하는 조성물에 관한 것으로서, 피부 조직에 처리하였을 때 뛰어난 콜라겐 생성 효과를 나타내고, 피부 조직을 수복시키는 것을 촉진 하는 조성물에 관한 것이다.
Abstract translation: 本说明书涉及促进产生胶原蛋白的组合物，包括作为一种糖胺聚糖的硫酸软骨素和透明质酸，并且涉及当组合物处理皮肤组织时对胶原产生具有优异效果的组合物 并促进皮肤组织的恢复。
-
公开(公告)号：KR1020130057640A
公开(公告)日：2013-06-03
申请号：KR1020110123485
申请日：2011-11-24
Applicant: (주)아모레퍼시픽
CPC classification number: C08L5/08 , A61K9/06 , A61K47/36 , A61L15/28 , A61L27/20 , A61L2400/06 , C08B37/0072 , A61K9/10 , A61K47/50
Abstract: PURPOSE: A method for preparing a water-insoluble gel composition is provided to minimize molecular weight reduction of polysaccharides using a small amount of a crosslinking agent and to ensure excellent strength and stability. CONSTITUTION: A method for preparing a water-insoluble gel composition comprises: a step of mixing water-soluble polysaccharides, an epoxy crosslinking agent, a basic compound, and a solvent; and a step of drying the mixture under vacuum at 1-30 deg. C to remove the solvent. The vacuum pressure is 1-30 mmHg. The solvent is removed by concentrating the water soluble polysaccharides in a concentration of 50-99 wt%. The molecular weight of the water soluble polysaccharides is 500-5,000 kDa. [Reference numerals] (AA) Volume of gel(%); (BB) Example 11
Abstract translation: 目的：提供一种制备水不溶性凝胶组合物的方法，以尽量减少使用少量交联剂的多糖的分子量降低并确保优异的强度和稳定性。 构成：制备水不溶性凝胶组合物的方法包括：将水溶性多糖，环氧交联剂，碱性化合物和溶剂混合的步骤; 以及在1-30度的真空下干燥混合物的步骤。 C去除溶剂。 真空压力为1-30mmHg。 通过浓缩50-99重量％的水溶性多糖来除去溶剂。 水溶性多糖的分子量为500-5,000kDa。 （标号）（AA）凝胶体积（％）; （BB）实施例11
-
公开(公告)号：KR1020130056838A
公开(公告)日：2013-05-30
申请号：KR1020120132975
申请日：2012-11-22
Applicant: (주)아모레퍼시픽
CPC classification number: A61K38/18 , A61K8/64 , A61K9/0014 , A61K38/30 , A61Q11/00 , A61Q19/02 , A61Q19/08 , A61K2300/00
Abstract: PURPOSE: A skin regeneration promoting agent containing epidermal growth factor(EGF), platelet-derived growth factor-AA(PDGF-AA), and insulin-like growth factor 1(IGF-1) is provided to promote skin regeneration and wound healing, and to minimize scar. CONSTITUTION: A skin regeneration promoting agent contains EGF, PDGF-AA, and IGF-1. The skin regeneration promoting agent further contains one or more growth factors among TGF(transforming growth factor beta) and FGF(fibroblast growth factor). The skin regeneration promoting agent promotes wound healing and regeneration of keratinocyte or fibroblast. A cosmetic composition or a pharmaceutical composition contains the skin regeneration promoting agent. [Reference numerals] (AA) Wound fill percentage(%); (BB) Control group
Abstract translation: 目的：提供含有表皮生长因子（EGF），血小板衍生生长因子-AA（PDGF-AA）和胰岛素样生长因子1（IGF-1）的皮肤再生促进剂，以促进皮肤再生和伤口愈合， 并尽量减少疤痕。 构成：皮肤再生促进剂含有EGF，PDGF-AA和IGF-1。 皮肤再生促进剂还含有TGF（转化生长因子β）和FGF（成纤维细胞生长因子）中的一种或多种生长因子。 皮肤再生促进剂促进角质形成细胞或成纤维细胞的伤口愈合和再生。 化妆品组合物或药物组合物含有皮肤再生促进剂。 （附图标记）（AA）伤口填充百分比（％）; （BB）对照组
-
-
-
-
-
-
-
-
-
Search Results
71
records
(took 0.035 seconds)
